Acknowledgement
Supported by : Korea University College of Medicine
References
- Chang DT, Challacombe B, Lawrentschuk N. Transperineal biopsy of the prostate--is this the future? Nat Rev Urol 2013;10:690-702. https://doi.org/10.1038/nrurol.2013.195
- Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018;378:1767-77. https://doi.org/10.1056/NEJMoa1801993
- Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet 2017;389:815-22. https://doi.org/10.1016/S0140-6736(16)32401-1
- Kawakami S, Kihara K, Fujii Y, Masuda H, Kobayashi T, Kageyama Y. Transrectal ultrasound-guided transperineal 14- core systematic biopsy detects apico-anterior cancer foci of T1c prostate cancer. Int J Urol 2004;11:613-8. https://doi.org/10.1111/j.1442-2042.2004.00863.x
- Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92. https://doi.org/10.1016/j.eururo.2013.05.049
- Huang H, Wang W, Lin T, Zhang Q, Zhao X, Lian H, et al. Comparison of the complications of traditional 12 cores transrectal prostate biopsy with image fusion guided transperineal prostate biopsy. BMC Urol 2016;16:68. https://doi.org/10.1186/s12894-016-0185-z
- Acher P, Dooldeniya M. Prostate biopsy: will transperineal replace transrectal? BJU Int 2013;112:533-4. https://doi.org/10.1111/bju.12299
- de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. AJR Am J Roentgenol 2014;202:343-51. https://doi.org/10.2214/AJR.13.11046
- Rodriguez-Covarrubias F, Gonzalez-Ramirez A, Aguilar-Davidov B, Castillejos-Molina R, Sotomayor M, Feria-Bernal G. Extended sampling at first biopsy improves cancer detection rate: results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy. J Urol 2011;185:2132-6. https://doi.org/10.1016/j.juro.2011.02.010
- Grummet JP, Weerakoon M, Huang S, Lawrentschuk N, Frydenberg M, Moon DA, et al. Sepsis and 'superbugs': should we favour the transperineal over the transrectal approach for prostate biopsy? BJU Int 2014;114:384-8.
- Takashima R, Egawa S, Kuwao S, Baba S. Anterior distribution of Stage T1c nonpalpable tumors in radical prostatectomy specimens. Urology 2002;59:692-7. https://doi.org/10.1016/S0090-4295(02)01525-X
- Satoh T, Matsumoto K, Fujita T, Tabata K, Okusa H, Tsuboi T, et al. Cancer core distribution in patients diagnosed by extended transperineal prostate biopsy. Urology 2005;66:114-8.
- Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert DL, Curtis R, et al. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. Eur Urol 2007;52:715-23. https://doi.org/10.1016/j.eururo.2007.02.041
- Feliciano J, Teper E, Ferrandino M, Macchia RJ, Blank W, Grunberger I, et al. The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? J Urol 2008;179:952-5; discussion 955. https://doi.org/10.1016/j.juro.2007.10.071
- Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, et al. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naive patients. BJU Int 2017;119:225-33. https://doi.org/10.1111/bju.13465
- Sonn GA, Chang E, Natarajan S, Margolis DJ, Macairan M, Lieu P, et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen. Eur Urol 2014;65:809-15. https://doi.org/10.1016/j.eururo.2013.03.025
- Ahmed HU, Kirkham A, Arya M, Illing R, Freeman A, Allen C, et al. Is it time to consider a role for MRI before prostate biopsy? Nat Rev Clin Oncol 2009;6:197-206. https://doi.org/10.1038/nrclinonc.2009.18
- Graham J, Kirkbride P, Cann K, Hasler E, Prettyjohns M. Prostate cancer: summary of updated NICE guidance. BMJ 2014;348:f7524. https://doi.org/10.1136/bmj.f7524
- Ghai S, Trachtenberg J. MRI-guided biopsies and minimally invasive therapy for prostate cancer. Indian J Urol 2015;31:209-16. https://doi.org/10.4103/0970-1591.159615
- Hamdy FC, Donovan JL, Lane JA, Mason M, Metcalfe C, Holding P, et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415-24. https://doi.org/10.1056/NEJMoa1606220
- Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, et al. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011;60:291-303. https://doi.org/10.1016/j.eururo.2011.05.006
- Montorsi F, Wilson TG, Rosen RC, Ahlering TE, Artibani W, Carroll PR, et al. Best practices in robot-assisted radical prostatectomy: recommendations of the Pasadena Consensus Panel. Eur Urol 2012;62:368-81. https://doi.org/10.1016/j.eururo.2012.05.057
- Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderang U, Thorsteinsdottir T, et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled, nonrandomised trial. Eur Urol 2015;68:216-25. https://doi.org/10.1016/j.eururo.2015.02.029
- Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ 2016;352:i851.
- Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensitymodulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008;70:1124-9. https://doi.org/10.1016/j.ijrobp.2007.11.044
- Wortel RC, Incrocci L, Pos FJ, Lebesque JV, Witte MG, van der Heide UA, et al. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 2015;91:737-44. https://doi.org/10.1016/j.ijrobp.2014.12.017
- Bokhorst LP, Valdagni R, Rannikko A, Kakehi Y, Pickles T, Bangma CH, et al. A Decade of active surveillance in the PRIAS study: an update and evaluation of the criteria used to recommend a switch to active treatment. Eur Urol 2016;70:954-60. https://doi.org/10.1016/j.eururo.2016.06.007
- Lindner U, Trachtenberg J. Focal therapy for localized prostate cancer -choosing the middle ground. Can Urol Assoc J 2009;3:333-5.
- Hausmann D, Aksoz N, von Hardenberg J, Martini T, Westhoff N, Buettner S, et al. Prostate cancer detection among readers with different degree of experience using ultra-high b-value diffusion-weighted Imaging: is a non-contrast protocol sufficient to detect significant cancer? Eur Radiol 2018;28:869-76. https://doi.org/10.1007/s00330-017-5004-8